Both targeted therapies and immunotherapy attack cancer cells without affecting healthy cells, so they can be used to treat male breast cancer. There are some differences between these two approaches.
Targeted cancer therapies are treatments that target specific characteristics of cancer cells, such as a protein that allows the cancer cells to grow in a rapid or abnormal way. Targeted therapies are generally less likely than chemotherapy to harm normal, healthy cells. Some targeted therapies are antibodies that work like the antibodies made naturally by our immune systems. These types of targeted therapies are sometimes called immune targeted therapies.
Learn more about the following targeted therapies that may be used to treat male breast cancer, including how each one works and any associated side effects:
- Afinitor (chemical name: everolimus)
- Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki)
- Herceptin (chemical name: trastuzumab)
- Ibrance (chemical name: palbociclib)
- Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine)
- Kisqali (chemical name: ribociclib)
- Lynparza (chemical name: olaparib)
- Margenza (chemical name: margetuximab-cmkb)
- Nerlynx (chemical name: neratinib)
- Perjeta (chemical name: pertuzumab)
- Phesgo (chemical name: pertuzumab, trastuzumab, and hyaluronidase-zzxf)
- Piqray (chemical name: alpelisib)
- Talzenna (chemical name: talazoparib)
- Trodelvy (chemical name: sacituzumab govitecan-hziy)
- Tukysa (chemical name: tucatinib)
- Tykerb (chemical name: (lapatinib)
- Verzenio (chemical name: abemaciclib)
Immunotherapy medicines use the power of your body’s immune system to attack cancer cells.
Keytruda is used in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer. Unresectable means that the cancer can’t be removed with surgery.
Keytruda also is used in combination with chemotherapy before surgery, and then on its own after surgery to treat early-stage triple-negative breast cancer with a high risk of recurrence (the cancer coming back).
Jemperli is used to treat mismatch repair deficient (dMMR) advanced-stage breast cancer that has grown during or after treatment if no other treatment options are available. Fewer than 1% of breast cancers have the dMMR biomarker.
Can we help guide you?
Create a profile for better recommendations
Breast self-exam, or regularly examining your breasts on your own, can be an important way to...
What Is Breast Implant Illness?
Breast implant illness (BII) is a term that some women and doctors use to refer to a wide range...
Tamoxifen (Brand Names: Nolvadex, Soltamox)
Tamoxifen is the oldest and most-prescribed selective estrogen receptor modulator (SERM)....